News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
378,808 Results
Type
Article (29470)
Company Profile (361)
Press Release (348969)
Multimedia
Podcasts (104)
Webinars (11)
Section
Business (99604)
Career Advice (362)
Deals (16521)
Drug Delivery (62)
Drug Development (65506)
Employer Resources (42)
FDA (8442)
Job Trends (7132)
News (185607)
Policy (13947)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (3)
Academia (1664)
Academic (1)
Accelerated approval (27)
Adcomms (23)
Allergies (88)
Alliances (28197)
ALS (158)
Alzheimer's disease (1283)
Antibody-drug conjugate (ADC) (325)
Approvals (8666)
Artificial intelligence (315)
Autoimmune disease (144)
Automation (20)
Bankruptcy (129)
Best Places to Work (6277)
BIOSECURE Act (9)
Biosimilars (141)
Biotechnology (275)
Bladder cancer (137)
Brain cancer (57)
Breast cancer (522)
Cancer (4430)
Cardiovascular disease (277)
Career advice (312)
Career pathing (12)
CAR-T (300)
CDC (8)
Cell therapy (816)
Cervical cancer (24)
Clinical research (55738)
Collaboration (1387)
Company closure (3)
Compensation (709)
Complete response letters (50)
COVID-19 (1693)
CRISPR (95)
C-suite (625)
Cystic fibrosis (135)
Data (5323)
Denatured (21)
Depression (98)
Diabetes (301)
Diagnostics (2634)
Digital health (15)
Diversity (5)
Diversity, equity & inclusion (12)
Drug discovery (224)
Drug pricing (61)
Drug shortages (5)
Duchenne muscular dystrophy (218)
Earnings (38968)
Editorial (29)
Employer branding (5)
Employer resources (40)
Events (65355)
Executive appointments (692)
FDA (10583)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1112)
Gene editing (203)
Generative AI (23)
Gene therapy (620)
GLP-1 (580)
Government (1754)
Grass and pollen (3)
Guidances (204)
Healthcare (8952)
HIV (31)
Huntington's disease (46)
IgA nephropathy (80)
Immunology and inflammation (233)
Immuno-oncology (54)
Indications (87)
Infectious disease (1844)
Inflammatory bowel disease (169)
Inflation Reduction Act (11)
Influenza (63)
Intellectual property (194)
Interviews (61)
IPO (8901)
IRA (17)
Job creations (1185)
Job search strategy (257)
JPM (51)
Kidney cancer (16)
Labor market (27)
Layoffs (346)
Leadership (12)
Legal (1968)
Liver cancer (79)
Longevity (13)
Lung cancer (652)
Lymphoma (379)
Machine learning (32)
Management (11)
Manufacturing (522)
MASH (137)
Medical device (3670)
Medtech (3693)
Mergers & acquisitions (8371)
Metabolic disorders (818)
Multiple sclerosis (143)
NASH (15)
Neurodegenerative disease (271)
Neuropsychiatric disorders (72)
Neuroscience (2344)
Neurotech (1)
NextGen: Class of 2026 (2663)
Non-profit (1479)
Now hiring (34)
Obesity (365)
Opinion (158)
Ovarian cancer (157)
Pain (119)
Pancreatic cancer (204)
Parkinson's disease (265)
Partnered (20)
Patents (366)
Patient recruitment (396)
Peanut (47)
People (31792)
Pharmaceutical (53)
Pharmacy benefit managers (7)
Phase 1 (19169)
Phase 2 (25462)
Phase 3 (17102)
Pipeline (3919)
Policy (117)
Postmarket research (1263)
Preclinical (8389)
Press Release (59)
Prostate cancer (187)
Psychedelics (50)
Radiopharmaceuticals (264)
Rare diseases (764)
Real estate (2247)
Recruiting (16)
Regulatory (13287)
Reports (24)
Research institute (1666)
Resumes & cover letters (57)
Rett syndrome (27)
RNA editing (21)
RSV (31)
Schizophrenia (124)
Series A (193)
Series B (145)
Service/supplier (3)
Sickle cell disease (104)
Special edition (20)
Spinal muscular atrophy (140)
Sponsored (29)
Startups (2316)
State (1)
Stomach cancer (16)
Supply chain (46)
Tariffs (26)
The Weekly (82)
Vaccines (537)
Venture capital (75)
Weight loss (196)
Women's health (38)
Worklife (5)
Date
Last 7 days (413)
Last 30 days (1486)
Last 365 days (21732)
2026 (2006)
2025 (22053)
2024 (25277)
2023 (27800)
2022 (33883)
2021 (35312)
2020 (30377)
2019 (21821)
2018 (16059)
2017 (18483)
2016 (16683)
2015 (19919)
2014 (14571)
2013 (11550)
2012 (11837)
2011 (11606)
2010 (10666)
Location
Africa (239)
Alabama (72)
Alaska (4)
Arizona (104)
Arkansas (6)
Asia (24406)
Australia (4575)
California (8359)
Canada (2123)
China (928)
Colorado (314)
Connecticut (307)
Delaware (290)
Europe (54172)
Florida (1077)
Georgia (241)
Hawaii (3)
Idaho (24)
Illinois (491)
India (39)
Indiana (185)
Iowa (15)
Japan (330)
Kansas (89)
Kentucky (17)
Louisiana (9)
Maine (62)
Maryland (902)
Massachusetts (6567)
Michigan (132)
Minnesota (300)
Mississippi (3)
Missouri (44)
Montana (21)
Nebraska (10)
Nevada (65)
New Hampshire (26)
New Jersey (2131)
New Mexico (19)
New York (2168)
North Carolina (1035)
North Dakota (9)
Northern California (4104)
Ohio (211)
Oklahoma (15)
Oregon (27)
Pennsylvania (1514)
Puerto Rico (11)
Rhode Island (27)
South America (364)
South Carolina (10)
Southern California (3291)
Tennessee (65)
Texas (1235)
United States (28349)
Utah (157)
Virginia (187)
Washington D.C. (42)
Washington State (767)
West Virginia (1)
Wisconsin (58)
378,808 Results for "brainstorm cell therapeutics inc.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
ALS
ALS Community Petitions FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival Data
BrainStorm Cell Therapeutics issued a statement Tuesday supporting a Citizens’ Petition submitted to the FDA requesting the approval of its cell therapy NurOwn, whose BLA was withdrawn in 2023. A Phase IIIb trial was scheduled to begin last month.
July 8, 2025
·
3 min read
·
Heather McKenzie
ALS
Patients Fight for Access to BrainStorm’s ALS Drug After Expanded Access Data ‘Defy Logic’
Participants in trials of BrainStorm Cell Therapeutics’ NurOwn filed a Citizens’ Petition with the FDA earlier this month seeking a new review of the stem cell therapy that was rejected in 2022 based on real-world data and 90% survival in an expanded access program.
July 17, 2025
·
9 min read
·
Heather McKenzie
Pharm Country
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it will hold a mid-year corporate update to discuss recent positive developments in the NurOwn® program on Monday, July 8, at 8:00 a.m. U.S. Eastern Time.
July 1, 2024
·
4 min read
Drug Development
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial
BrainStorm Cell Therapeutics Inc. ment with the U.S. Food and Drug Administration (FDA) on the Chemistry, Manufacturing, and Controls (CMC) aspects of Brainstorm’s Phase 3b clinical trial for NurOwn.
June 26, 2024
·
4 min read
Business
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced the appointment of Hartoun Hartounian Ph.D. as its new EVP and COO, effective as of June 18, 2024.
June 20, 2024
·
6 min read
Pharm Country
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
BrainStorm Cell Therapeutics Inc announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 11,111,111 shares of the Company’s common stock at a purchase price of $0.36 per share in a registered direct offering.
June 27, 2024
·
5 min read
Pharm Country
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced that it will hold a conference call to update shareholders on the NurOwn® program tomorrow, April 9, at 8:00 AM Eastern Time.
April 8, 2024
·
4 min read
Business
Stem Cell Specialist PrimeGen Takes SPAC Track to Nasdaq
The SPAC agreement values PrimeGen US at $1.5 billion in equity and gives it capital to advance its pre-clinical triple-activated mesenchymal stem cell pipeline into the clinic.
February 5, 2026
·
1 min read
·
Tristan Manalac
Business
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the First Quarter ended March 31, 2024 and provided a corporate update.
May 14, 2024
·
10 min read
Business
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
BrainStorm Cell Therapeutics Inc. today announced financial results for the full year ended December 31, 2023 and provided a corporate update.
April 1, 2024
·
9 min read
1 of 37,881
Next
